Côd QR

Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation

Background: Etanercept, infliximab and adalimumab are licensed in the UK for the treatment of active and progressive psoriatic arthritis (PsA) in adults who have an inadequate response to standard treatment. Objective: To determine the clinical effectiveness, safety and cost-effectiveness of these b...

Disgrifiad llawn

Wedi'i Gadw mewn:
Prif Awduron: M Rodgers, D Epstein, L Bojke, H Yang, D Craig, T Fonseca, L Myers, I Bruce, R Chalmers, S Bujkiewicz, M Lai, N Cooper, K Abrams, D Spiegelhalter, A Sutton, M Sculpher, N Woolacott
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: NIHR Journals Library 2011-02-01
Cyfres:Health Technology Assessment
Pynciau:
etanercept
infliximab
adalimumab
psoriatic arthritis
systematic review
economic evaluation
Mynediad Ar-lein:https://doi.org/10.3310/hta15100
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg